Application No.: 09/724,953 Amdt. Submitted on May 27, 2003 Reply to Office Action of November 27, 2002

PATENT

This listing of claims will replace all prior versions, and listings of claims in the application:

## Listing of Claims:

Claims1-10: (Withdrawn)

Claim 11. (Currently Amended) A method of preventing or treating a disorder characterized by amyloid deposition of  $A\beta$  peptide in a mammalian subject, comprising administering to the subject a dosage of an agent effective to produce an immune response comprising antibodies against an amyloid component characteristic of said disorder, wherein the amyloid component is  $A\beta$  peptide and an adjuvant that augments the immune response to the  $A\beta$  peptide, and thereby preventing or treating the disorder.

Claims 12-13: (Canceled)

Claim 14. (Currently Amended) The method of claim 1311, wherein said agent induces an immune response directed against a necepitope formed by said amyloid component with respect to said amyloid precursor protein.

Claim 15. (Canceled)

Claim 16. (Currently Amended) The method of claim 1558, wherein said agent is selected from the group consisting of AA, AL, ATTR, AapoA1, Agel, Acys, Aβ or a fragment thereof, AB<sub>2</sub>M, AScr, Acal, AIAPP and synuclein NAC fragment.

Claim 17. (Canceled)

Claim 18. (Currently Amended) The method of claim 17 16, wherein said administering includes administering at least two a second amyloid fibril components.

Claim 19. (Currently Amended) The method of claim 1158, wherein said agent is a peptide linked to a carrier protein.

Claim 20. (Canceled)

Application No.: 09/724,953 Amdt. Submitted on May 27, 2003 Reply to Office Action of November 27, 2002

PATENT

- Claim 21. (Currently Amended) The method of claim 2011, wherein said adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, and alum and Fround's adjuvant.
- Claim 22. (Currently Amended) The method of claim 11, wherein said immunological immune response is characterized by a serum titer of the antibodies of at least 1:1000 with respect to said amyloid component.
- Claim 23. (Currently Amended) The method of claim 22, wherein said serum titer of the antibodies is at least 1:5000 with respect to said fibril amyloid component.
- Claim 24. (Currently Amended) The method of claim 11, wherein said immunelogical immune response is characterized by a serum amount titer of immunereactivity the antibodies corresponding to greater than about four times higher than a serum level titer of immunereactivity anti-  $A\beta$  antibodies measured in a pre-treatment control serum sample.
- Claim 25. (Currently Amended) The method of claim 24, wherein said serum amount titer of immunereactivity the antibodies is measured at a serum dilution of about 1:100.

Claims 26-57: (Canceled)

Claim 58. (New) The method of claim 11, wherein the disorder is hereditary Alzheimer's disease, Down's syndrome, hereditary cerebral hemorrhage(Dutch type), sporadic cerebral amyloid angiopathy, or inclusion body myositis.

